MapLight Therapeutics (MPLT) Assets Average (2025 - 2026)
MapLight Therapeutics (MPLT) posted Assets Average of $368.4 million for Q4 2025, up 86.92% sequentially from $197.1 million in Q3 2025.
Powered by 
Analysis
MapLight Therapeutics (MPLT) Assets Average (2025 - 2026) Analysis & Trends
MapLight Therapeutics has reported Assets Average for 1 years, with the latest figure at $368.4 million in Q4 2025.
- Quarterly Assets Average changed N/A year-over-year to $368.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $368.4 million (changed N/A YoY) and the FY2025 annual result came in at $308.2 million, changed N/A from the prior year.
- Assets Average climbed to $368.4 million in Q4 2025 per MPLT's latest filing, from $197.1 million in the prior quarter.
- Over five years, Assets Average peaked at $368.4 million in Q4 2025 and troughed at $197.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | MapLight Therapeutics | 642.40 Mn | 642.40 Mn | - | 423.93 Mn |